Video
Dr. Moyad on the history of vitamin D trials in urology
Author(s):
“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.
Video Player is loading.
In this interview, Mark A. Moyad, MD, MPH discusses the 2011 Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the recently completed VITamin D and OmegA-3 TriaL (VITAL), both of which explored the impact of vitamin D on urologic endpoints. Moyad is the Jenkins/Pomkempner Director of Complementary Alternative Medicine in the Department of Urology at the University of Michigan Medical Center.
Related Videos
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
Related Content
